GET THE APP

Journal of Antivirals & Antiretrovirals

Journal of Antivirals & Antiretrovirals
Open Access

ISSN: 1948-5964

+44 1300 500008

Journal of Antivirals & Antiretrovirals : Citations & Metrics Report

Articles published in Journal of Antivirals & Antiretrovirals have been cited by esteemed scholars and scientists all around the world. Journal of Antivirals & Antiretrovirals has got h-index 22, which means every article in Journal of Antivirals & Antiretrovirals has got 22 average citations.

Following are the list of articles that have cited the articles published in Journal of Antivirals & Antiretrovirals.

  2022 2021 2020 2019 2018

Year wise published articles

32 59 77 13 11

Year wise citations received

172 256 226 169 197
Journal total citations count 1776
Journal impact factor 5.32
Journal 5 years impact factor 5.62
Journal cite score 5.3
Journal h-index 22
Journal h-index since 2018 17
Important citations (1101)

ross r, stidham aw, saenyakul p, kleman c (2015) clinicalresearchinhiv aidsandprevention clinicalresearchinhiv aidsandprevention clinicalresearchinhiv aidsandprevention.

olowofela a, fourrier-réglat a, isah ao (2016) pharmacovigilance in nigeria: an overview. pharmaceutical medicine. 30: 87-94.

bezabhe wm, bereznicki lr, chalmers l, gee p, kassie dm, et al. (2015) adverse drug reactions and clinical outcomes in patients initiated on antiretroviral therapy: a prospective cohort study from ethiopia. drug safety 38: 629-639.

ogoina d, obiako ro, muktar hm, adeiza m, babadoko a, et al. (2012) morbidity and mortality patterns of hospitalised adult hiv/aids patients in the era of highly active antiretroviral therapy: a 4-year retrospective review from zaria, northern nigeria. aids research and treatment.

shubber z, calmy a, andrieux-meyer i, vitoria m, renaud-théry f, et al. (2013) adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. aids 27: 1403-1412.

chawana td, katzenstein d, nathoo k, ngara b, nhachi cf (2017) evaluating an enhanced adherence intervention among hiv positive adolescents failing atazanavir/ritonavir-based second line antiretroviral treatment at a public health clinic. journal of aids and hiv research 9: 17-30.

jansen k, sönnerborg a, brockmeyer n, thalme a, svedhem v, et al. (2013) long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with hiv type 1 infection. aids research and human retroviruses 29: 564-573.

establishment and application of evaluation model of mitochondrial toxicity in hepg2 cells with galactose as growth energy (2013) chinese journal of pharmacology bulletin 29: 1617-1621.

rahul j (2011) research and reviews: journal of pharmaceutics and nanotechnology.

patrikar s, shankar s, kotwal a, basannar dr, bhatti v, et al. (2017) predictors of first line antiretroviral therapy failure and burden of second line antiretroviral therapy. medical journal armed forces india 73: 5-11.

the mechanism and clinical manifestation of mitochondrial toxicity of nucleoside analogues (2013) chinese journal of pharmacology and toxicology 27: 885-888.

mujahid m, ghani f. research & reviews: journal of medical and health sciences 54: 55.

pustylnikov sv (2011) endociosis and the supervisory response of macrophages in experimental models of hiv infection and tuberculosis under the influence of decasts.

naga anusha p (2011) antiretroviral strategies for treatment of hiv. j antivir antiretrovir 1: 2.

pustylnikov s, dave rs, khan zk, porkolab v, rashad aa, et al. (2016) short communication: inhibition of dc-sign-mediated hiv-1 infection by complementary actions of dendritic cell receptor antagonists and env-targeting virus inactivators. aids research and human retroviruses 32: 93-100.

sehgal m, khan zk, talal ah, jain p (2013) dendritic cells in hiv-1 and hcv infection: can they help win the battle? virology: research and treatment 4: 1.

lambert aa, azzi a, lin sx, allaire g, st-gelais kp, et al. (2013) dendritic cell immunoreceptor is a new target for anti-aids drug development: identification of dcir/hiv-1 inhibitors. plos one 8: e67873.

pustylnikov s, sagar d, jain p, khan zk (2014) targeting the c-type lectins-mediated host-pathogen interactions with dextran. journal of pharmacy & pharmaceutical sciences 17: 371-392.

zhou x, liu j, yang b, lin x, yang xw, et al. (2013) marine natural products with anti-hiv activities in the last decade. current medicinal chemistry. 20: 953-973.

thépaut m, guzzi c, sutkeviciute i, sattin s, ribeiro-viana r, et al. (2013) structure of a glycomimetic ligand in the carbohydrate recognition domain of c-type lectin dc-sign. structural requirements for selectivity and ligand design. journal of the american chemical society 135: 2518-2529.

Relevant Topics

Top